sb 203580 has been researched along with prostaglandin h2 in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (prostaglandin h2) | Trials (prostaglandin h2) | Recent Studies (post-2010) (prostaglandin h2) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 413 | 0 | 34 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Börsch-Haubold, AG; Pasquet, S; Watson, SP | 1 |
1 other study(ies) available for sb 203580 and prostaglandin h2
Article | Year |
---|---|
Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase.
Topics: Arachidonic Acid; Calcium-Calmodulin-Dependent Protein Kinases; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Flavonoids; Humans; Imidazoles; In Vitro Techniques; Isoenzymes; Membrane Proteins; Platelet Activation; Prostaglandin H2; Prostaglandin-Endoperoxide Synthases; Prostaglandins H; Pyridines; Thromboxane A2; Thromboxane-A Synthase | 1998 |